Medtronic plc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Geoffrey Straub Martha
- Full Time Employees
- 95,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building Two, Parkmore Business Park West Galway GA Ireland H91 4K49
- IPO Date
- Nov 21, 1977
- CIK
- 0001613103
- Website
- medtronic.com
- Similar Companies
- Business
- Medtronic plc (NYSE: MDT) develops, manufactures, and markets a wide range of medical devices and therapies for the treatment of chronic diseases worldwide. The company offers products across four main segments: cardiovascular (including pacemakers, defibrillators, heart valves, and coronary stents under brands such as Evera, Protecta, and CoreValve); medical surgical (featuring surgical navigation systems, endoscopic tools, and stapling devices like Hugo RAS and Valiant NaviCore); neuroscience (encompassing spinal cord stimulators, deep brain stimulation systems, and intrathecal drug delivery pumps such as Incepta and SynchroMed II); and diabetes (primarily continuous glucose monitoring systems, insulin pumps, and related software through the MiniMed and Guardian brands). Medtronic provides services including patient management software, remote monitoring platforms, and clinical decision support tools to healthcare providers, hospitals, clinics, and patients globally. Founded in 1949 and headquartered in Dublin, Ireland, with principal executive offices in Minneapolis, Minnesota, USA, Medtronic operates in more than 150 countries, serving markets in North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales forces, distributors, and subsidiaries. The company targets physicians, hospitals, ambulatory surgery centers, and home care settings, with a focus on minimally invasive therapies and digital health solutions. Key subsidiaries include Covidien (acquired in 2015 for surgical and patient monitoring products) and Intersect ENT (recently integrated for sinus implants). In the past 1-2 years, Medtronic has pursued strategic expansions including the FDA approval and U.S. launch of the Hugo robotic-assisted surgery (RAS) system in 2024 for soft tissue indications, building on its European CE Mark; a multi-year collaboration with NVIDIA announced in 2024 to advance AI-enabled therapies using Medtronic's Gigamon data platform; and the acquisition of Mazor Robotics in 2018 followed by ongoing enhancements to its spinal robotics portfolio with the Mazor X Stealth Edition. The company completed a $4.1 billion acquisition of Covidien assets integration and reported expansions in diabetes care via the Simplera Sync sensor FDA clearance in 2024. Medtronic also announced organizational realignments in 2025 to streamline its four operating units amid portfolio optimization efforts.
Company News
Medtronic to announce financial results for its second quarter of fiscal year 2027
These 12 stocks are good bets to beat the 10-year Treasury over the next decade
TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study
Medtronic PLC $MDT Stock: Heritage Investors Management Corp Reduces Stake
Hennessy Advisors Inc. Sells 31,426 Shares of Medtronic PLC $MDT
Medtronic (MDT) Ascends While Market Falls: Some Facts to Note
The Best Dividend Stocks to Buy With $5,000 in November
Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?
Why the Market Dipped But Medtronic (MDT) Gained Today
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
American Century Equity Income Fund Q3 2026 Portfolio Activity
Medtronic: Broader Growth, Attractive Valuation
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?
A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.17 vs Price $96.59
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
Arlington Financial Advisors LLC Acquires 9,743 Shares of Medtronic PLC $MDT
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning